WO2005099761A1 - Dietary supplement and method of processing same - Google Patents

Dietary supplement and method of processing same Download PDF

Info

Publication number
WO2005099761A1
WO2005099761A1 PCT/US2005/010466 US2005010466W WO2005099761A1 WO 2005099761 A1 WO2005099761 A1 WO 2005099761A1 US 2005010466 W US2005010466 W US 2005010466W WO 2005099761 A1 WO2005099761 A1 WO 2005099761A1
Authority
WO
WIPO (PCT)
Prior art keywords
resveratrol
small molecules
biologically active
composition
encapsulated composition
Prior art date
Application number
PCT/US2005/010466
Other languages
French (fr)
Inventor
Bill Sardi
Stan Solomonson
Original Assignee
Resveratrol Partners, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resveratrol Partners, Llc filed Critical Resveratrol Partners, Llc
Priority to CN2005800107544A priority Critical patent/CN1956733B/en
Priority to JP2007507358A priority patent/JP4963670B2/en
Priority to EP05731006A priority patent/EP1735004A4/en
Publication of WO2005099761A1 publication Critical patent/WO2005099761A1/en
Priority to KR1020067020587A priority patent/KR101213141B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/70Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/704Polygonum, e.g. knotweed
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23PSHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00Shaping or working of foodstuffs characterised by the products
    • A23P10/30Encapsulation of particles, e.g. foodstuff additives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/87Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Definitions

  • the present invention relates to an encapsulated composition including biologically active small molecules and a method of processing the composition to maintain biological activity and, in particular, to maintain its ability to activate (express) or deactivate (silence) the Sirtuin 1 gene.
  • BACKGROUND Resveratrol is a naturally occurring phenolic fungicide produced by some plants in response to injury or fungal infection. It is one of a group of compounds (called phytoalexins) produced in plants during times of environmental stress such as adverse weather or attacks by insects, animals, or pathogenic microorganisms (e.g., fungi). Resveratrol is the parent molecule of a family of polymers called viniferins.
  • resveratrol content of a wine depends not only on the type of grape, but also on the length of time the grape skins/seeds are present during the fermentation process (i.e., the amount of time the skins/seeds are left in contact with the juice).
  • the resveratrol concentration is significantly (approximately ten times) higher in red wine than in white wine because during red wine production, the skins/seeds are left in contact with the juice for a longer period of time, increasing the a-mount of resveratrol from the skins/seeds.
  • the total resveratrol concentration may range from 0.6 to 15 mg/1.
  • resveratrol is biologically active, providing several health benefits including cancer prevention, anti-inflammatory properties, and cardiovascular effects.
  • Resveratrol functions as a moderate antioxidant, quenching free radical damage linked to several cancers.
  • Resveratrol also inhibits the transcription factor NF- ⁇ B, which stimulates genes responsible for cell survival, inflammation, and proliferation of cancer.
  • NF- ⁇ B transcription factor
  • resveratrol sensitizes them to tumor necrosis factor- ⁇ , which initiates apoptosis (cell death).
  • Epidemiological, in vitro, and animal studies also suggest that a high resveratrol intake is associated with a reduced incidence of cardiovascular disease (producing antiplatelet and hypolipidemic effects).
  • resveratrol increases the life span of yeast, worms, and mice by slowing cellular degeneration. It has been suggested that 3 to 15 milligrams of resveratrol (the amount present in 3-5 glasses of red wine) is believed to be sufficient to produce the above effects. In order to provide the aforementioned benefits, however, the resveratrol, once produced, must remain biologically active. Maintaining the biological activity of resveratrol is difficult. Resveratrol has a half-life of about one day; consequently, upon exposure to the ambient environment, it completely oxidizes within two days. Once oxidized, its ability to affect biological systems diminishes.
  • raw resveratrol When used in dietary supplements, raw resveratrol is genexally produced as an alcohol extract from plant sources (e.g., Giant Knotweed), which is then dried into a powder, encapsulated or put into pill form, which, in turn, are sealed in airtight packaging.
  • plant sources e.g., Giant Knotweed
  • resveratrol as a raw material generally exhibits effective biological activity, when the resveratrol powder is mixed and blended in the process of encapsulation, it is exposed to oxygen, eventually losing some if not all of its biological activity " before it can reach the consumer.
  • HPLC high performance liquid chromatography
  • resveratrol may lack significant biological activity.
  • resveratrol may exhibit certain antioxidant, estrogen-like, cholesterol-controlling effect s, it loses its genomic biological activity.
  • Enzymatic biological activity e.g., the ability to activate and deactivate human enzymes
  • has been demonstrated only in preserved resv ⁇ eratrol molecules e.g., as the molecules exist is in wine or in research-grade resveratrol.
  • a dietary supplement including stabilized resveratrol that retains its biological activity and, in particular, its enzymatic biological activity.
  • an object of the present invention is to provide an encapsulated composition including a biologically active resveratrol, and to a method of encapsulating the composition such that the resveratrol remains biologically active when ingested by a consumer. It is another object of the invention to provide a method of encapsulating small molecule plant polyphenols capable of stimulating enzymatic activity such that the enzymatic activity is preserved. It is a further object of the invention to provide an encapsulated composition having a genomic effect, including activation and/or deactivation of human enzymes.
  • a dietary supplement including an encapsulated resveratrol composition in which the efficacy of the resveratrol is maintained by preventing its exposure to oxygen during the encapsulation process.
  • a still further object of the present invention is to prevent metal-induced oxidation of dietary supplement ingredients during the processing and packaging of the supplement .
  • the embodiments of the present invention provide an encapsulated composition including (1) small molecules of a plant or synthetic source in their biologically active form and (2) optionally at least one of (a) an emulsifier, (b) an antioxidant, and (c) a chelating agent.
  • the embodiments further provide a method of encapsulating a compo sition including the steps of (1) deriving material including biologically active small molecules derived from a plant source or formed synthetically and (2) encapsulating the material dn a substantially oxygen-free environment.
  • deriving material including biologically active small molecules derived from a plant source or formed synthetically
  • encapsulating the material dn a substantially oxygen-free environment.
  • the biologically active small molecules of plant or synthetic source may include small molecule plant polyphenols such as resveratrol, quercetin, fisetin, butein, piceatonol, isoliquiritigenin, which, by virtue of their small size and molecular weight, are able to pass through cell walls, enter the cell nucleus, and alter certain gene-controlled mechanisms.
  • a preferred small molecule plant polyphenol is resveratrol (molecular weight 228.25), which has been shown to activate Sirtuin-1 controlled enzyme activity better than other polyphenols.
  • Resveratrol may be formed synthetically or derived naturally from sources such as plant material, including grapes and knotweed.
  • the resveratrol includes the trans stereoisomer of the molecule, namely, trans-3,4' -,5 trihydoxystilbene, which possesses the following chemical structure:
  • the small molecules of plant or synthetic source preferably remain biologically active for time periods after which the molecules would naturally become biologically inactive due to degradative processes such as oxidation.
  • resveratrol possesses a half-life of approximately one day; consequently, it typically loses significant biological activity within two days of exposure to ambient conditions and during processing of dietary supplements.
  • Another embodiment of the invention relates to a method of encapsulating small molecules of plant or synthetic source including the steps of (1) deriving mate_rial including small molecules of plant or synthetic source; (2) encapsulating the material in a substantially oxygen-free environment; and (3) optionally adding (a) a chelating agent, (b) an.
  • the material including small molecules may be derived naturally or synthetically formed.
  • the material moreover, should be biologically active.
  • Biological activity is intended to include the ability of the small molecules to pass through -a cell wall, enter the cell nucleus, and beneficially alter gene-controlled enzymes, in particular, the Sirtuin 1 enzyme.
  • the biologically active material is naturally derived, i.e., derived from at least one natural source such as plants (or parts thereof, such as tubers or fruit (including pulp and skins) from the plant).
  • One preferred source is the seeds and/or skins of grapes, such as Nitis vinifera, Nitis labrusca, and Nitis rotundifolia.
  • Another preferred source is Polygonum (Giant Knotweed) and, in particular, 1 -polygonum cuspidatum (a species of giant knotweed).
  • the natural derivation process includes those processes generally known in the art, including an extraction process in which a solvent is used to extract the small molecules from a natural source.
  • the solvent includes aqueous solvents, organic solvents, and mixtures thereof.
  • the solvent may include, but is not limited to, alcohols sixch as ethanol.
  • the extracted small molecule material may include aqueous or organic solvent extracts of plants (or parts thereof), fruit juices (e.g., grape juice), and fermented liquors (e.g. wine) produced from plants or fruit juice, or mixtures of any of the foregoing.
  • the extracted material may further include inert plant material naturally removed during the extraction process.
  • the extracted material may be processed (physically and/or chemically) to remove the solvent and increase the concentration of the small molecules.
  • the solvent may be removed from the extract (e.g., by drying), leaving a dried powder.
  • the derived material including small molecules is then encapsulated in a substantially oxygen-free environment.
  • the phrase "substantially oxygen-free" is intended to include environments having less than less than about 100 parts per million oxygen.
  • the encapsulation process would take place immediately after the extraction or formation of the small molecules and be shielded from exposure to light, heat, and oxygen.
  • the material including small molecules may be stored in a substantially oxygen-free environment until encapsulated.
  • the encapsulation process includes the steps of (1) providing a capsule including a head portion and a body portion; (2) at least partially filling the body portion with the material including biologically active small molecules; (3) axially positioning th-e head portion over the body portion such that the portions at least partially overlap; and (4) forming a fluid tight (air and liquid impermeable) seal along the overlapping portions.
  • the material comprising the capsule portions is not particularly limited.
  • the capsule portions comprise material possessing a low oxygen transmission rate.
  • the capsule portions comprise a material having an oxygen transmission rate (as measured by ASTM D3985) of less than about 165 cm 3 /rrx 2 /day for 100 ⁇ m, more preferably less than about 4 cm 3 /m 2 /day for 100 ⁇ m, and most preferably less than about 1 cm /m /day for 100 ⁇ m.
  • Exemplary materials comprising the capsule portions include, but are not limited to, an ingestible material such as gelatin, hydroxypropyl methylcellulose, or starch.
  • the material may include- e gelatin having an oxygen transmission rate of about 3.5 cm 3 /m 2 /day for 100 ⁇ m.
  • the resulting capsules may include hard gelatin capsules or soft gelatin capsules having an oxygen transmission rate of up to about 0.04 cm 3 /capsule/day (ASTM D3985 at 27°C and rel. humidity of 50%).
  • opaque capsules are highly preferred. This can be achieved- by adding pigment such as titanium dioxide to the capsule material formulation. Titanium- dioxide is inert and possesses a high molecular weight, which prevents it from being absorbed into blood circulation when ingested.
  • Opaque capsules function to prevent the degradation of the resveratrol-containing composition by light degenerative processes such as pho-tooxidation.
  • a commercially available, opaque capsule having low oxygen permeability is available from Capsugel (Greenwood, SC— www.capsugel.com), sold under the trade name Licaps®.
  • the system used to encapsulate the composition including biologically active small molecules material must create a fluid-tight (air and liquid impermeable) seal a-round capsule portions.
  • a particularly preferred encapsulation system and process is disclosed in WO 01/08631 Al , incorporated herein by reference in its entirety. In this system and associated process, a capsule head portion and a capsule body portion are placed in a filliixg chamber. The capsule body portion is filled with the desired dosage material, and the cap sule portions are then telescopically joined such that the head portion partially overlaps the body portion.
  • a sealing liquid including a solvent is applied in the gap formed between the overlapping sections, and the capsule is dried to remove the solvent and form a fluid-tight seal.
  • the encapsulation process occurs in a substantially oxygen-free environment, hi addition, it is preferred the encapsulation process take place in a darkened (substantially light free) environment.
  • small molecules such as resveratrol lose their biological activity upon exposure to light and/or oxygen (due, e.g., to oxidation processes). Consequently, the composition containing small molecules should be mixed and/or encapsulated in a system including airtight and darkened mbcing and filling chambers having a substantially oxygen-free environment.
  • Oxygen may be removed using a vacuum, replacing the oxygen within the system with an inert gas flush, or a combination thereof.
  • the system can be purged of oxygen using a controlled nitrogen blanket.
  • the system is kept substantially oxygen free through the use of a nitrogen flush during the encapsulation process.
  • a nitrogen purge may also be used to remove oxygen from each individual capsule. Specifically, prior to sealing, a positive pressure can be applied to each capsule to replace any oxygen present within the capsule with nitrogen. Upon sealing, a nitrogen bubble remains within the capsule.
  • a commercially available enc apsulation system capable of filling capsules in a substantially oxygen-free and light-free environment is available from Capsugel (Greenwood, SC— www.capsugel.com), sold under the trade name CPS 1000 Capsule Filling Machine.
  • the above process produces an encapsulated composition suitable as an orally ingestible dosage of biologically active small molecules (e.g., resveratrol).
  • the composition including the biologically active small molecules may include up to 100% " by weight small molecule material.
  • the composition may contain additives to stabilize the biological activity of the small molecules, to improve their biological availability upon ingestion, and/or to improve their absorption and passage through biological barriers.
  • the composition may include one or more of (1) a chelating agent, (2) an antioxidant, and (3) an emulsifier.
  • a chelating agent (chelator) may be added to further preserve the biological activity of the small molecule material by preventing metal-induced oxidation.
  • Oxygen in the presence of metals such as iron, may be reduced to hydrogen peroxide by phenols.
  • Hydrogen peroxide in turn, may oxidize small molecules such as resveratrol and quercetin.
  • Metals such as iron have special oxygen transfer properties, which, when combined with hydrogen peroxide, produce a more reactive and destructive form of iron, namely, Fe 3+ .
  • an iron II (Fe 2+ ) salt reacts with hydrogen peroxide to form an iron III (Fe 3+ ) salt and a highly reactive hydroxyl radical. Consequently, it is believed obstructing the Fenton reaction can bio ck the oxidation of small molecules derived from a plant or synthetic source (e.g., resveratrol and quercetin).
  • a chelating agent e.g., a metal chelator such as NDGA (nordihydroguaiaretic acid: l,4-bis[3,4-dihydroxyphenyl]2.,3dimethylbutane) functions to counter the oxidation of resveratrol by hydrogen peroxide.
  • NDGA functions, in part, by converting the more reactive form of iron (Fe 3+ ) to its less reactive form (Te 2+ ).
  • Fe 3+ more reactive form of iron
  • Te 2+ less reactive form
  • Phytic acid also called inositol hexaphosphate
  • Phytic acid is an iron-binding molecule typically used as a food preservative due to its ability to block iron-driven oxidation, similar to the action of NDGA.
  • phytic acid functions as a metal chelator that minimizes, if not prevents, the occurrence of the Fenton reaction.
  • Phytic Acid is a naturally derived material that conies from whole grains and seeds of plant sources, including corn, wheat, rice, soybean, sesame, and oat.
  • the amount of chelating agent is not particularly limited, so long as it is sufficient to bind metals within the composition.
  • the chelating agent may be present in a range of about 0 - 25% by weight, more preferably in a range of about 5 - 15% by weight, and most preferably in a range of about 7-10% by weight.
  • an antioxidant may be added to the composition not only to provide additional biological activity to the composition, but also to prevent the degradation of the composition caused by oxidation.
  • the normal processes o oxidation (plus a minor contribution from ionizing radiation) produce highly reactive free radicals. These can readily react with and damage other molecules. In some cases, the body uses this to fight infection, i other cases, the damage may continue to the body's own cells.
  • the composition may include a phenolic antioxidant such as a flavonoid.
  • the composition may include a flavanol compound such as quercetin.
  • Quercetin in addition to having antioxidant properties, is a small molecule plant polyphenol that exhibits enzymatic biological activity (incli ⁇ ding sirtuin enzyme activation) similar to that of resveratrol. Quercetin also functions to prohibit the sulfation of resveratrol once ingested.
  • the amount of antioxidant in the composition is not particularly limited.
  • the antioxidant may be present in a range of about 0 - 50%) by weight, more preferably in a range of about 15 - 35% by weight, and most preferably in a range of about 20 - 30 % by weight.
  • An emulsifier may be added to the composition to enhance the bioavailability of the composition (i.e., to enhance the ability of the body to absorb and use the small molecules once ingested).
  • the emulsifier may comprise a phospholipid- such as lecithin (phosphatidylcholine).
  • the amount of emulsifier present in the composition is preferably in the range of about 0 - 50% by weight, more preferably in an amount of 15 - 45% by weight, and most preferably in a range of about 25% > - 40% by weight.
  • the amount of nxaterial including small molecules is preferably in a range of about 1 - 70%> by weight, m-ore preferably in a range of about 5 - 30%) by weight, and most preferably in an amount of about 10 - 20%o by weight.
  • the amount of resveratrol available for oral consumption is preferably in the range of about 3 to 70 mg.
  • the additives may be combined with the material including small molecules at any tim-e before the capsule is sealed.
  • the material including small molecules resveratrol material may be extracted, dried, mixed with an additive, and then encapsulated.
  • the additives may be placed in the capsule before or after the material includin-g small molecules is placed in a capsule.
  • the resulting capsules may be packaged to prevent degradation of the small molecules in the event a capsule ruptures.
  • the capsules may be individually enclosed in a blister pack including an airtight compartment.
  • a substantially oxygen-free environment can be maintained within the container by adding an oxygen absorbing packet capable of maintaining the amount of free oxygen within the bottle to less than about 100 parts per million or less.
  • any packaging used is flushed with nitrogen before sealed.
  • the present invention comprises a practical, economic method of maintaining the biological activity of components present in a composition containing small molecule plant polyphenols such as resveratrol by preventing the degradation of the components.
  • inventive compositions and processes are believed to maintain the biological activity of the composition by preventing oxidation caused by oxidizing metals (i.e., metals naturally found in dietary supplement formulas, or metals provided in trace amounts as part of herbal extracts, or metals on surfaces of formulation, mixing and encapsulation machinery), which can trigger or accelerate the oxidation (spoilage) of the composition and destroy the biological activity of the components.
  • oxidizing metals i.e., metals naturally found in dietary supplement formulas, or metals provided in trace amounts as part of herbal extracts, or metals on surfaces of formulation, mixing and encapsulation machinery
  • This is further achieved by stabilizing the ingredient(s) in question against metal-induced oxidation through the addition of a chelating agent, and, as noted above, performing the handling and encapsulation of the dietary supplement in a substantially oxygen-free environment.
  • the small molecules present in the inventive encapsulated compositions maintain biological activity for substantial time periods after the normal life of the small molecules. For example, under ambient conditions, the half-life of resveratrol is approximately one day. In the manufacture and distribution of dietary supplements, however, it typically takes several weeks after encapsulation before the composition reaches a consumer.
  • the embodiments of the instant invention form dietary supplements including small molecules that remain biological active upon reaching the consumer. In particular, it forms dietary supplements including resveratrol capable of enzymatic biological activity.
  • the small molecules remain biologically active for at least about four months after encapsulation, more preferably at least about eight months after encapsulation, and most preferably at least about one year or indefinitely.
  • biologically active small molecules derived from a plant source or formed synthetically, as well as compositions containing biologically active small molecules, provide various health benefits.
  • biologically active small molecules are capable of enzymatic activity, activating human "longevity genes".
  • longevity genes a class of regulatory genes that are shared by almost all living organisms. These genes function as a feedback system to enhance survival during times of stress, such as during drought or famine. Once activated, these longevity genes induce defensive changes at the cellular level, such as slowing metabolism and enhancing cellular respiration, to help the body adapt to an adverse environment.
  • One particular stress the restriction of calories provided to an organism, extends lifespan in numerous species by activating enzymes (or proteins) called sirtuins (a family of deacetylases).
  • sirtuins (Silent Information Regulator enzymes) act as longevity genes due to their ability to control the rate of aging in organisms such as such as yeast, roundworms, and fruit flies.
  • SIR2 Silicon Information Regulator gene 2
  • SIR2 Small Information Regulator gene 2
  • yeast cells which is homolgous to Sirtuin 1 in humans, becomes activated when under biological stress.
  • aging is directly linked to SIR2 activity.
  • Overexpression of SIR2 increases DNA stability, increases silencing and suppression of rDNA recombination, speeds cellular repairs, and enhances mother-daughter cell replicative lifespan.
  • Sirtuin 1 which is located in the nucleus, is a human sirtuin- having the greatest homology to SIR2. Human sirtuins appear to act as guardian enzymes that protect cells and enhance cellular survival. SIRTl, for example, has been shown to suppxess the p53 enzyme system normally involved in suppressing tumor growth and instigating cell death (apoptosis). Inhibiting the activity of a tumor suppressor gene may not be readily deemed to be beneficial until it is recognized that SIRTl inhibition prevents the cycle of premature aging and apoptosis normally.
  • SIRTl By suppressing p53 activity, SIRTl prevents the cycle of premature aging and apoptosis normally induced when cellular DNA is dam-aged or stressed, thus giving cells enough time to repair any damage and prevent unnecessary cell death.
  • small molecules such as resveratrol are capable of activating SIR2.
  • resveratrol decreases rDNA recombination and extends lifespan, similar to that which occurs during calorie restriction.
  • Small molecules such as resveratrol moreover, have been shown to activate SIRTl in human cells, enhancing the survival rate of cells stressed by irradiation.
  • a dietary supplement including a composition formed and encapsulated using the above-described process, to activate longevity genes, namely the sirtuin enzymes SIR2 and SIRTl.
  • the activation of the SIRTl enzyme increases the survival rates of human cells, suppressing apoptosis.
  • the encapsulated compositions including small molecules are suitable for use in making dietary supplements, as well as prescription medications.
  • Example Small molecules in the form of resveratrol were obtained "via ethanol extraction from vitis vinifera and polygonum cuspidatum. The ethanol was remo ed, and the resulting extract comprised approximately 25%o vinis vinifera skin resveratrol and 25% polygonum cuspidatum resveratrol, with the remainder comprising non-resvexatrol, inert plant material.
  • the biological activity of the resveratrol in the extract was confirmed using a SIRTl Fluorescent Activity Assay/Drug Discovery Kit AK-555 (available from Biomol® Research Laboratories, hie; Plymouth Meeting, PA; www.biomol.com).
  • the extract was kept in a nitrogen environment and added to a mixture including approximately 25 %> by weight quercetin; 33%o by weight lecithin; and 9% phytic acid (in the form of rice bran extract). The remainder of the composition included approximately 33%> by weight resveratrol extract.
  • the resulting slurry was placed into a capsule-filling machine. Individual dosages were encapsulated in gelatin capsules tinted with titanium oxide (Licaps® capsules available from Capsugel; Greenwood, SC; www.capsugel.com).
  • the dosages were encapsulated in a substantially oxygen- free environment using a capsule-filling machine continually flushed with nitrogen (the Capsugel CFS 1000 Capsule Filling and Sealing Machine, available from Capsugel; Greenwood, SC; www.capsugel.com).
  • Each resulting capsule included at least 15 mg resveratrol, 100 mg lecithin, 75 mg quercetin, and 25 mg pb-ytic acid.
  • These capsule samples were stored under ambient conditions for approximately eight months.
  • the samples were tested for biological activity by determining whether each sample could activate sirtuin enzymes and, in particular, whether the samples stimulated SIRTl catalytic activity. The samples were tested four months and eight months after encapsulation.
  • Tests were performed using a SIRTl Fluorescent Activity Assay/Drug Discovery Kit -A-K-555 (available from Biomol® Research Laboratories, Inc.; Madison Meeting, PA; xyww.biomol.com). Upon testing, it was determined that the resveratrol contained within the samples was biologically active, stimulating SIRTl activity, producing up to about an eight-fold stimulation in enzymatic activity compared to when no resveratrol is present. Similarly, the biological activity of the quercetin was tested, and it was determined that the encapsulated quercetin maintained biological activity (i.e., the ability to stimulate SIRTT activity compared to when no quercetin is present).
  • the invention is comprised of multiple methods of manufacturing and preserving maximum biological activity (including having the ability to activate sirtuin enzymes) and the structural form of plant polyphenols and other dietary supplement ingredients against degradation (via, e.g., oxidation), including but not limited to tlxe manufacture of raw material and its placement into capsules.
  • the above-described method economically produces an encapsulated composition including concentrated resveratrol having properties similar to that made available in research-grade resveratrol or resveratrol as it exists in a sealed wine bottle.
  • the present invention is useful in manufacturing encapsulated formulations that can be ingested as a dietary supplement.
  • the capsule may be of any shape and size, and may be made breakable to enable the removal of the composition from the capsule.
  • the capsule material moreover, may comprise any material having a low oxygen transmission rate.
  • the comp ositions including small molecules may exist as a dried powder, a liquid suspension, a gel, or a slurry.
  • the formulations may include other additives, fillers, etc. suitable for dietary supplement formulations, so long as the additives do not degrade the biological activity or the bioavailabilty of the material including small molecules.

Abstract

A composition including small plant or synthetic molecules, such as resveratrol and quercetin, in their biologically active form, is provided. The small molecules may be derived from natural sources such as grapes or Giant Knotweed (botanical name Polygonum). The composition may be processed such that the gene-controlled biological activity of the small molecules is maintained. Specifically, the raw material for encapsulation must exhibit biological activity before and after encapsulation and be processed in an oxygen-free (nitrogen), dim light environment. The composition may further include at least one metal chelating agent as an antioxidant stabilizer, an antioxidant, and an emulsifier. The compositions are useful in the formation of a dietary supplement or drug.

Description

DIETARY SUPPLEMENT AND METHOD OF PROCESSING SAME CROSS REFERENCE TO RELATED APPLICATIONS This application claims priority from U.S. Provisional Patent Application Serial No. 60/59,955, entitled "Dietary Supplement and Method of Processing Same" and filed October 23, 2003. The disclosure of the above-mentioned provisional application is incorporated herein by reference in its entirety.
FIELD OF THE INVENTION The present invention relates to an encapsulated composition including biologically active small molecules and a method of processing the composition to maintain biological activity and, in particular, to maintain its ability to activate (express) or deactivate (silence) the Sirtuin 1 gene. BACKGROUND Resveratrol is a naturally occurring phenolic fungicide produced by some plants in response to injury or fungal infection. It is one of a group of compounds (called phytoalexins) produced in plants during times of environmental stress such as adverse weather or attacks by insects, animals, or pathogenic microorganisms (e.g., fungi). Resveratrol is the parent molecule of a family of polymers called viniferins. Its natural sources include pine trees, eucalyptus plants, knotweed, Liliaceae, Polygonaceae, Leguminosae, mulberries, peanuts, blueberries, cranberries, and pine-kernels. Its most abundant natural sources are Vitis vinifera, Vitis labrusca, and Nitis rotundifolia (muscadine), all of which are grape varieties used to make wine. Resveratrol (Cι42O3), also known as 3,4',5 trihydroxystilbene, naturally exists in cis- and trans-stereoisomeric forms. In grapes and wine, resveratrol is present mainly in its trans stereoisomeric form. During the manufacturing process of wine, fermentation takes place while the seeds and skins of the grapes are left in contact with the pressed juice. Ethanol, created during the fermentation process, naturally extracts and concentrates resveratrol from the skins and seeds. The resveratrol content of a wine depends not only on the type of grape, but also on the length of time the grape skins/seeds are present during the fermentation process (i.e., the amount of time the skins/seeds are left in contact with the juice). The resveratrol concentration is significantly (approximately ten times) higher in red wine than in white wine because during red wine production, the skins/seeds are left in contact with the juice for a longer period of time, increasing the a-mount of resveratrol from the skins/seeds. In a typical (750 ml) bottle of red wine, the total resveratrol concentration may range from 0.6 to 15 mg/1. Once formed, the resveratrol is preserved within the wine by its via its packaging and processing, namely, it is stored in an airtight bottle substantially impervious to light. The bottles themselves, moreover, are typically stored in cool, darkened environments (e.g., a wine cellar). Studies have shown that resveratrol is biologically active, providing several health benefits including cancer prevention, anti-inflammatory properties, and cardiovascular effects. Resveratrol functions as a moderate antioxidant, quenching free radical damage linked to several cancers. Resveratrol also inhibits the transcription factor NF-κB, which stimulates genes responsible for cell survival, inflammation, and proliferation of cancer. When applied to cancer cells, resveratrol sensitizes them to tumor necrosis factor-α, which initiates apoptosis (cell death). Epidemiological, in vitro, and animal studies also suggest that a high resveratrol intake is associated with a reduced incidence of cardiovascular disease (producing antiplatelet and hypolipidemic effects). More recent studies suggest resveratrol increases the life span of yeast, worms, and mice by slowing cellular degeneration. It has been suggested that 3 to 15 milligrams of resveratrol (the amount present in 3-5 glasses of red wine) is believed to be sufficient to produce the above effects. In order to provide the aforementioned benefits, however, the resveratrol, once produced, must remain biologically active. Maintaining the biological activity of resveratrol is difficult. Resveratrol has a half-life of about one day; consequently, upon exposure to the ambient environment, it completely oxidizes within two days. Once oxidized, its ability to affect biological systems diminishes. When used in dietary supplements, raw resveratrol is genexally produced as an alcohol extract from plant sources (e.g., Giant Knotweed), which is then dried into a powder, encapsulated or put into pill form, which, in turn, are sealed in airtight packaging. Although resveratrol as a raw material generally exhibits effective biological activity, when the resveratrol powder is mixed and blended in the process of encapsulation, it is exposed to oxygen, eventually losing some if not all of its biological activity "before it can reach the consumer. As a result, even though the resveratrol molecule may "be confirmed to be present after encapsulation by high performance liquid chromatography (HPLC), it may or may not exhibit gene-controlled biological activity. Consequently, even tlxough resveratrol may be present in the supplement, it may lack significant biological activity. In particular, while resveratrol may exhibit certain antioxidant, estrogen-like, cholesterol-controlling effect s, it loses its genomic biological activity. Enzymatic biological activity (e.g., the ability to activate and deactivate human enzymes) has been demonstrated only in preserved resv^eratrol molecules (e.g., as the molecules exist is in wine or in research-grade resveratrol).
Consequently, it is desirable to provide a dietary supplement including stabilized resveratrol that retains its biological activity and, in particular, its enzymatic biological activity.
OBJECTS AND SUMMARY OF THE INVENTION Therefore, in light of the above, and for other reasons that become apparent w ren the invention is described, an object of the present invention is to provide an encapsulated composition including a biologically active resveratrol, and to a method of encapsulating the composition such that the resveratrol remains biologically active when ingested by a consumer. It is another object of the invention to provide a method of encapsulating small molecule plant polyphenols capable of stimulating enzymatic activity such that the enzymatic activity is preserved. It is a further object of the invention to provide an encapsulated composition having a genomic effect, including activation and/or deactivation of human enzymes. It is yet another object of the invention to provide a dietary supplement including an encapsulated resveratrol composition in which the efficacy of the resveratrol is maintained by preventing its exposure to oxygen during the encapsulation process. A still further object of the present invention is to prevent metal-induced oxidation of dietary supplement ingredients during the processing and packaging of the supplement . Generally, the embodiments of the present invention provide an encapsulated composition including (1) small molecules of a plant or synthetic source in their biologically active form and (2) optionally at least one of (a) an emulsifier, (b) an antioxidant, and (c) a chelating agent. The embodiments further provide a method of encapsulating a compo sition including the steps of (1) deriving material including biologically active small molecules derived from a plant source or formed synthetically and (2) encapsulating the material dn a substantially oxygen-free environment. The above and still further objects, features and advantages of the present irrvention will become apparent upon consideration of the following detailed description of specific embodiments thereof. DETAILED DESCRIPTION One embodiment of the invention relates to a composition including small molecules derived from a plant or formed synthetically, and a method of encapsulating the composition such that it maintains its biological activity for extended periods of time. The biologically active small molecules of plant or synthetic source may include small molecule plant polyphenols such as resveratrol, quercetin, fisetin, butein, piceatonol, isoliquiritigenin, which, by virtue of their small size and molecular weight, are able to pass through cell walls, enter the cell nucleus, and alter certain gene-controlled mechanisms. A preferred small molecule plant polyphenol is resveratrol (molecular weight 228.25), which has been shown to activate Sirtuin-1 controlled enzyme activity better than other polyphenols. However, other small molecules may be employed. Resveratrol may be formed synthetically or derived naturally from sources such as plant material, including grapes and knotweed. Preferab ly, the resveratrol includes the trans stereoisomer of the molecule, namely, trans-3,4' -,5 trihydoxystilbene, which possesses the following chemical structure:
Figure imgf000005_0001
To maintain biological activity for an "extended period" of time, the small molecules of plant or synthetic source preferably remain biologically active for time periods after which the molecules would naturally become biologically inactive due to degradative processes such as oxidation. For example, resveratrol possesses a half-life of approximately one day; consequently, it typically loses significant biological activity within two days of exposure to ambient conditions and during processing of dietary supplements. Another embodiment of the invention relates to a method of encapsulating small molecules of plant or synthetic source including the steps of (1) deriving mate_rial including small molecules of plant or synthetic source; (2) encapsulating the material in a substantially oxygen-free environment; and (3) optionally adding (a) a chelating agent, (b) an. antioxidant, and/or (c) an emulsifier to the material. As discussed above, the material including small molecules may be derived naturally or synthetically formed. The material, moreover, should be biologically active. Biological activity is intended to include the ability of the small molecules to pass through -a cell wall, enter the cell nucleus, and beneficially alter gene-controlled enzymes, in particular, the Sirtuin 1 enzyme. Preferably, the biologically active material is naturally derived, i.e., derived from at least one natural source such as plants (or parts thereof, such as tubers or fruit (including pulp and skins) from the plant). One preferred source is the seeds and/or skins of grapes, such as Nitis vinifera, Nitis labrusca, and Nitis rotundifolia. Another preferred source is Polygonum (Giant Knotweed) and, in particular, 1 -polygonum cuspidatum (a species of giant knotweed). The natural derivation process includes those processes generally known in the art, including an extraction process in which a solvent is used to extract the small molecules from a natural source. The solvent includes aqueous solvents, organic solvents, and mixtures thereof. The solvent may include, but is not limited to, alcohols sixch as ethanol. By way of specific examples, the extracted small molecule material may include aqueous or organic solvent extracts of plants (or parts thereof), fruit juices (e.g., grape juice), and fermented liquors (e.g. wine) produced from plants or fruit juice, or mixtures of any of the foregoing. The extracted material may further include inert plant material naturally removed during the extraction process. The extracted material may be processed (physically and/or chemically) to remove the solvent and increase the concentration of the small molecules. For example, the solvent may be removed from the extract (e.g., by drying), leaving a dried powder. The derived material including small molecules is then encapsulated in a substantially oxygen-free environment. As used herein, the phrase "substantially oxygen-free" is intended to include environments having less than less than about 100 parts per million oxygen. Ideally, the encapsulation process would take place immediately after the extraction or formation of the small molecules and be shielded from exposure to light, heat, and oxygen. Alternatively, the material including small molecules may be stored in a substantially oxygen-free environment until encapsulated. The encapsulation process includes the steps of (1) providing a capsule including a head portion and a body portion; (2) at least partially filling the body portion with the material including biologically active small molecules; (3) axially positioning th-e head portion over the body portion such that the portions at least partially overlap; and (4) forming a fluid tight (air and liquid impermeable) seal along the overlapping portions. The material comprising the capsule portions is not particularly limited. Preferably, the capsule portions comprise material possessing a low oxygen transmission rate. For example, it is preferred the capsule portions comprise a material having an oxygen transmission rate (as measured by ASTM D3985) of less than about 165 cm3/rrx2/day for 100 μm, more preferably less than about 4 cm3/m2/day for 100 μm, and most preferably less than about 1 cm /m /day for 100 μm. Exemplary materials comprising the capsule portions include, but are not limited to, an ingestible material such as gelatin, hydroxypropyl methylcellulose, or starch. By way of specific example, the material may inclu- e gelatin having an oxygen transmission rate of about 3.5 cm3/m2/day for 100 μm. The resulting capsules may include hard gelatin capsules or soft gelatin capsules having an oxygen transmission rate of up to about 0.04 cm3/capsule/day (ASTM D3985 at 27°C and rel. humidity of 50%). In addition, opaque capsules are highly preferred. This can be achieved- by adding pigment such as titanium dioxide to the capsule material formulation. Titanium- dioxide is inert and possesses a high molecular weight, which prevents it from being absorbed into blood circulation when ingested. Opaque capsules function to prevent the degradation of the resveratrol-containing composition by light degenerative processes such as pho-tooxidation. A commercially available, opaque capsule having low oxygen permeability is available from Capsugel (Greenwood, SC— www.capsugel.com), sold under the trade name Licaps®. The system used to encapsulate the composition including biologically active small molecules material must create a fluid-tight (air and liquid impermeable) seal a-round capsule portions. A particularly preferred encapsulation system and process is disclosed in WO 01/08631 Al , incorporated herein by reference in its entirety. In this system and associated process, a capsule head portion and a capsule body portion are placed in a filliixg chamber. The capsule body portion is filled with the desired dosage material, and the cap sule portions are then telescopically joined such that the head portion partially overlaps the body portion. A sealing liquid including a solvent is applied in the gap formed between the overlapping sections, and the capsule is dried to remove the solvent and form a fluid-tight seal. It is important to the invention that the encapsulation process occurs in a substantially oxygen-free environment, hi addition, it is preferred the encapsulation process take place in a darkened (substantially light free) environment. As explained above, small molecules such as resveratrol lose their biological activity upon exposure to light and/or oxygen (due, e.g., to oxidation processes). Consequently, the composition containing small molecules should be mixed and/or encapsulated in a system including airtight and darkened mbcing and filling chambers having a substantially oxygen-free environment. This can be achieved by using an enclosed system from which oxygen is removed. Oxygen may be removed using a vacuum, replacing the oxygen within the system with an inert gas flush, or a combination thereof. For example, the system can be purged of oxygen using a controlled nitrogen blanket. In addition, the system is kept substantially oxygen free through the use of a nitrogen flush during the encapsulation process. A nitrogen purge may also be used to remove oxygen from each individual capsule. Specifically, prior to sealing, a positive pressure can be applied to each capsule to replace any oxygen present within the capsule with nitrogen. Upon sealing, a nitrogen bubble remains within the capsule. A commercially available enc apsulation system capable of filling capsules in a substantially oxygen-free and light-free environment is available from Capsugel (Greenwood, SC— www.capsugel.com), sold under the trade name CPS 1000 Capsule Filling Machine. The above process produces an encapsulated composition suitable as an orally ingestible dosage of biologically active small molecules (e.g., resveratrol). The composition including the biologically active small molecules may include up to 100% "by weight small molecule material. In addition, the composition may contain additives to stabilize the biological activity of the small molecules, to improve their biological availability upon ingestion, and/or to improve their absorption and passage through biological barriers. For example, the composition may include one or more of (1) a chelating agent, (2) an antioxidant, and (3) an emulsifier. A chelating agent (chelator) may be added to further preserve the biological activity of the small molecule material by preventing metal-induced oxidation. Oxygen, in the presence of metals such as iron, may be reduced to hydrogen peroxide by phenols. Hydrogen peroxide, in turn, may oxidize small molecules such as resveratrol and quercetin. Metals such as iron have special oxygen transfer properties, which, when combined with hydrogen peroxide, produce a more reactive and destructive form of iron, namely, Fe3+. In a Fenton reaction, an iron II (Fe2+) salt reacts with hydrogen peroxide to form an iron III (Fe3+) salt and a highly reactive hydroxyl radical. Consequently, it is believed obstructing the Fenton reaction can bio ck the oxidation of small molecules derived from a plant or synthetic source (e.g., resveratrol and quercetin). This can be achieved through the use of a chelating agent. For example, a metal chelator such as NDGA (nordihydroguaiaretic acid: l,4-bis[3,4-dihydroxyphenyl]2.,3dimethylbutane) functions to counter the oxidation of resveratrol by hydrogen peroxide. NDGA functions, in part, by converting the more reactive form of iron (Fe3+) to its less reactive form (Te2+). See Pinto et al., "Oxidation of Resveratrol Catalyzed by Soybean Lipoxygenase", J. j4gric. Food Chem., 51(6) (2003), 1653-1657; incorporated herein by reference in its entirety. Phytic acid (also called inositol hexaphosphate) is an iron-binding molecule typically used as a food preservative due to its ability to block iron-driven oxidation, similar to the action of NDGA. Similarly, phytic acid functions as a metal chelator that minimizes, if not prevents, the occurrence of the Fenton reaction. See Graf et al. "Phytic Acid: A Natural Antioxidant", J Biol. Chem., Aug 1987, 262: 11647 - 11650; incorporated herein, by reference in its entirety. Phytic Acid is a naturally derived material that conies from whole grains and seeds of plant sources, including corn, wheat, rice, soybean, sesame, and oat. The amount of chelating agent is not particularly limited, so long as it is sufficient to bind metals within the composition. By way of example, the chelating agent may be present in a range of about 0 - 25% by weight, more preferably in a range of about 5 - 15% by weight, and most preferably in a range of about 7-10% by weight. hi addition, an antioxidant may be added to the composition not only to provide additional biological activity to the composition, but also to prevent the degradation of the composition caused by oxidation. In biological systems, the normal processes o oxidation (plus a minor contribution from ionizing radiation) produce highly reactive free radicals. These can readily react with and damage other molecules. In some cases, the body uses this to fight infection, i other cases, the damage may continue to the body's own cells.
Consequently, the presence of an antioxidant can prevent free radicals from damaging the small molecules. By way of example, the composition may include a phenolic antioxidant such as a flavonoid. By way of further example, the composition may include a flavanol compound such as quercetin. Quercetin, in addition to having antioxidant properties, is a small molecule plant polyphenol that exhibits enzymatic biological activity (incliαding sirtuin enzyme activation) similar to that of resveratrol. Quercetin also functions to prohibit the sulfation of resveratrol once ingested. The amount of antioxidant in the composition is not particularly limited. By way of example, the antioxidant may be present in a range of about 0 - 50%) by weight, more preferably in a range of about 15 - 35% by weight, and most preferably in a range of about 20 - 30 % by weight. An emulsifier may be added to the composition to enhance the bioavailability of the composition (i.e., to enhance the ability of the body to absorb and use the small molecules once ingested). By way of example, the emulsifier may comprise a phospholipid- such as lecithin (phosphatidylcholine). The amount of emulsifier present in the composition is preferably in the range of about 0 - 50% by weight, more preferably in an amount of 15 - 45% by weight, and most preferably in a range of about 25%> - 40% by weight. When one or more additives are present, the amount of nxaterial including small molecules is preferably in a range of about 1 - 70%> by weight, m-ore preferably in a range of about 5 - 30%) by weight, and most preferably in an amount of about 10 - 20%o by weight. By way of specific example, in a standard dietary capsule, the amount of resveratrol available for oral consumption is preferably in the range of about 3 to 70 mg. The additives may be combined with the material including small molecules at any tim-e before the capsule is sealed. For example, the material including small molecules resveratrol material may be extracted, dried, mixed with an additive, and then encapsulated. Alternatively, the additives may be placed in the capsule before or after the material includin-g small molecules is placed in a capsule. Once the composition containing the small molecules is encapsulated, the resulting capsules may be packaged to prevent degradation of the small molecules in the event a capsule ruptures. For example, the capsules may be individually enclosed in a blister pack including an airtight compartment. Additionally, if the capsules are stored loosely in an airtight, vacuum-sealed container (e.g., a bottle), a substantially oxygen-free environment can be maintained within the container by adding an oxygen absorbing packet capable of maintaining the amount of free oxygen within the bottle to less than about 100 parts per million or less. Preferably, any packaging used is flushed with nitrogen before sealed. The present invention comprises a practical, economic method of maintaining the biological activity of components present in a composition containing small molecule plant polyphenols such as resveratrol by preventing the degradation of the components. Specifically, the inventive compositions and processes are believed to maintain the biological activity of the composition by preventing oxidation caused by oxidizing metals (i.e., metals naturally found in dietary supplement formulas, or metals provided in trace amounts as part of herbal extracts, or metals on surfaces of formulation, mixing and encapsulation machinery), which can trigger or accelerate the oxidation (spoilage) of the composition and destroy the biological activity of the components. This is further achieved by stabilizing the ingredient(s) in question against metal-induced oxidation through the addition of a chelating agent, and, as noted above, performing the handling and encapsulation of the dietary supplement in a substantially oxygen-free environment. The small molecules present in the inventive encapsulated compositions maintain biological activity for substantial time periods after the normal life of the small molecules. For example, under ambient conditions, the half-life of resveratrol is approximately one day. In the manufacture and distribution of dietary supplements, however, it typically takes several weeks after encapsulation before the composition reaches a consumer. The embodiments of the instant invention form dietary supplements including small molecules that remain biological active upon reaching the consumer. In particular, it forms dietary supplements including resveratrol capable of enzymatic biological activity. Preferably, the small molecules remain biologically active for at least about four months after encapsulation, more preferably at least about eight months after encapsulation, and most preferably at least about one year or indefinitely. Biologically active small molecules derived from a plant source or formed synthetically, as well as compositions containing biologically active small molecules, provide various health benefits. For example, biologically active small molecules are capable of enzymatic activity, activating human "longevity genes". Studies have identified a class of regulatory genes that are shared by almost all living organisms. These genes function as a feedback system to enhance survival during times of stress, such as during drought or famine. Once activated, these longevity genes induce defensive changes at the cellular level, such as slowing metabolism and enhancing cellular respiration, to help the body adapt to an adverse environment. One particular stress, the restriction of calories provided to an organism, extends lifespan in numerous species by activating enzymes (or proteins) called sirtuins (a family of deacetylases). Studies have shown that sirtuins (Silent Information Regulator enzymes) act as longevity genes due to their ability to control the rate of aging in organisms such as such as yeast, roundworms, and fruit flies. Specifically it has been shown that SIR2 (Silent Information Regulator gene 2) in yeast cells, which is homolgous to Sirtuin 1 in humans, becomes activated when under biological stress. In yeast, aging is directly linked to SIR2 activity. Overexpression of SIR2 increases DNA stability, increases silencing and suppression of rDNA recombination, speeds cellular repairs, and enhances mother-daughter cell replicative lifespan. There are seven human sirtuins, which have been designated Sirtuin 1 through Sirtuin 7. Sirtuin 1 (SIRTl), which is located in the nucleus, is a human sirtuin- having the greatest homology to SIR2. Human sirtuins appear to act as guardian enzymes that protect cells and enhance cellular survival. SIRTl, for example, has been shown to suppxess the p53 enzyme system normally involved in suppressing tumor growth and instigating cell death (apoptosis). Inhibiting the activity of a tumor suppressor gene may not be readily deemed to be beneficial until it is recognized that SIRTl inhibition prevents the cycle of premature aging and apoptosis normally. By suppressing p53 activity, SIRTl prevents the cycle of premature aging and apoptosis normally induced when cellular DNA is dam-aged or stressed, thus giving cells enough time to repair any damage and prevent unnecessary cell death. Studies, both in vitro and in vivo, have determined that small molecules such as resveratrol are capable of activating SIR2. In yeast, resveratrol decreases rDNA recombination and extends lifespan, similar to that which occurs during calorie restriction. Small molecules such as resveratrol, moreover, have been shown to activate SIRTl in human cells, enhancing the survival rate of cells stressed by irradiation. Consequently, maintaining biological activity of small molecules enables the dosage present in, e.g., a dietary supplement including a composition formed and encapsulated using the above-described process, to activate longevity genes, namely the sirtuin enzymes SIR2 and SIRTl. In humans, the activation of the SIRTl enzyme increases the survival rates of human cells, suppressing apoptosis. The encapsulated compositions including small molecules are suitable for use in making dietary supplements, as well as prescription medications.
Example Small molecules in the form of resveratrol were obtained "via ethanol extraction from vitis vinifera and polygonum cuspidatum. The ethanol was remo ed, and the resulting extract comprised approximately 25%o vinis vinifera skin resveratrol and 25% polygonum cuspidatum resveratrol, with the remainder comprising non-resvexatrol, inert plant material. The biological activity of the resveratrol in the extract was confirmed using a SIRTl Fluorescent Activity Assay/Drug Discovery Kit AK-555 (available from Biomol® Research Laboratories, hie; Plymouth Meeting, PA; www.biomol.com). The extract was kept in a nitrogen environment and added to a mixture including approximately 25 %> by weight quercetin; 33%o by weight lecithin; and 9% phytic acid (in the form of rice bran extract). The remainder of the composition included approximately 33%> by weight resveratrol extract. The resulting slurry was placed into a capsule-filling machine. Individual dosages were encapsulated in gelatin capsules tinted with titanium oxide (Licaps® capsules available from Capsugel; Greenwood, SC; www.capsugel.com). The dosages were encapsulated in a substantially oxygen- free environment using a capsule-filling machine continually flushed with nitrogen (the Capsugel CFS 1000 Capsule Filling and Sealing Machine, available from Capsugel; Greenwood, SC; www.capsugel.com). Each resulting capsule included at least 15 mg resveratrol, 100 mg lecithin, 75 mg quercetin, and 25 mg pb-ytic acid. These capsule samples were stored under ambient conditions for approximately eight months. The samples were tested for biological activity by determining whether each sample could activate sirtuin enzymes and, in particular, whether the samples stimulated SIRTl catalytic activity. The samples were tested four months and eight months after encapsulation. Tests were performed using a SIRTl Fluorescent Activity Assay/Drug Discovery Kit -A-K-555 (available from Biomol® Research Laboratories, Inc.; Plymouth Meeting, PA; xyww.biomol.com). Upon testing, it was determined that the resveratrol contained within the samples was biologically active, stimulating SIRTl activity, producing up to about an eight-fold stimulation in enzymatic activity compared to when no resveratrol is present. Similarly, the biological activity of the quercetin was tested, and it was determined that the encapsulated quercetin maintained biological activity (i.e., the ability to stimulate SIRTT activity compared to when no quercetin is present). The invention is comprised of multiple methods of manufacturing and preserving maximum biological activity (including having the ability to activate sirtuin enzymes) and the structural form of plant polyphenols and other dietary supplement ingredients against degradation (via, e.g., oxidation), including but not limited to tlxe manufacture of raw material and its placement into capsules. The above-described method economically produces an encapsulated composition including concentrated resveratrol having properties similar to that made available in research-grade resveratrol or resveratrol as it exists in a sealed wine bottle. The present invention is useful in manufacturing encapsulated formulations that can be ingested as a dietary supplement. While the invention has been described in detail and with reference to specific embodiments thereof, it will be apparent to one skilled in the art that various changes and modifications can be made therein without departing from the spirit and scope thereof. For example, the capsule may be of any shape and size, and may be made breakable to enable the removal of the composition from the capsule. The capsule material, moreover, may comprise any material having a low oxygen transmission rate. The comp ositions including small molecules, furthermore, may exist as a dried powder, a liquid suspension, a gel, or a slurry. hi addition, the formulations may include other additives, fillers, etc. suitable for dietary supplement formulations, so long as the additives do not degrade the biological activity or the bioavailabilty of the material including small molecules. In addition, other small molecule polyphenols capable of enzymatic activity (including stimulating the catalytic activity of sirtuins) may be encapsulated using the above-described process, including but not limited to quercetin, fisetin, butein, piceatonol, and isoliquiritigenin. Thus, it is intended that the present invention covers the modifications and variations of this invention that come within the scope of the appended claims and their equivalents.

Claims

We Claim:
1. A process of encapsulating a composition including the steps of: (a) deriving material including biologically active small molecules; and (b) encapsulating the biologically active small molecules in a substantially oxygen- free environment.
2. The process of claim 1, wherein the biologically active small molecules comprise resveratrol.
3. The process of claim 2 further including (c) combining the resveratrol with at least one of a chelating agent, an antioxidant, and an emulsifier.
4. The process of claim 2, wherein step (a) includes: (a.l) using a solvent to extract the resveratrol, wherein said solvent includes aqueous solvents, organic solvents, and mixtures thereof.
5. The process of claim 2, wherein step (b) includes: (b.l) receiving a capsule including a head portion and a body portion into an airtight filling chamber; (b.2) at least partially filling the body portion with a composition including the biologically active resveratrol; (b.3) positioning the head portion over the body portion such that the portions at least partially overlap; and (b.4) forming a fluid tight seal along the overlapping portions.
6. The process of claim 5, wherein the capsule portions comprise a material having an ooxxyyggeenn t trraamnsmission rate (as measured by ASTM D3985) of less than about 165 cm3/m2/day for 100 μm,
7. The process of claim 5, wherein the capsule portions comprise a material having an oxygen transmission rate (as measured by ASTM D3985) of less than about 4 cm3/m2/day for 100 μm.
8. The process of claim 5, wherein the capsule portions comprise a material having an oxygen fransmission rate (as measured by ASTM D3985) of less than about 1 cm3/m2/day for 100 μm.
9. The process of claim 5, wherein the capsule portions comprise at least one of gelatin, hydroxypropyl methylcellulose, and starch.
10. The process of claim 5, wherein step (b) further includes (b.5) forming a nitrogen blanket within said filling chamber to form the substantially oxygen-free environment.
11. The process of claim 4, wherein step (b) further includes (b.6) fonning a nitrogen bubble within the capsule prior to the sealing step.
12. The process of claim 2, wherein step (a) further inchxdes: (a.l) deriving said resveratrol from a natural source selected from the group consisting of Ninis Vinifera and Polygonum.
13. An encapsulated composition including biologically active small molecules, a chelating agent, an antioxidant, and an emulsifier, wherein the small molecules were encapsulated in a substantially oxygen-free environment.
14. The encapsulated composition of claim 13, wherein said biologically active small molecules comprise resveratrol.
15. The encapsulated composition of claim 14, wherein: said chelating agent is present in an amount of about 5 - 15% by weight, said antioxidant is present in an amount of about 15 - 35% by weight, said emulsifier is present in an amount of about 15 - -45% by weight, and said resveratrol is present in an amount of about 5 - 30% by weight.
16. The encapsulated composition of claim 14, wherein: said chelating agent is present in an amount of about 7 - 10% by weight, said antioxidant is present in an amount of about 20 - 30% by weight, said emulsifier is present in an amount of about 25 - 40% by weight, and said resveratrol is present in an amount of about 10 - 20% by weight.
17. The encapsulated composition of claim 14, wl erein said chelating agent comprises a compound capable of blocking metal-induced oxidation of resveratrol.
18. The encapsulated composition of claim 17, wlierein said chelating agent comprises at least one of phytic acid and NDGA.
19. The encapsulated composition of claim 14, wlierein said antioxidant comprises a phenolic antioxidant.
20. The encapsulated composition of claim 19, wlierein said phenolic antioxidant comprises quercetin.
21. The encapsulated composition of claim 14, wherein said emulsifier comprises lecithin (phosphatidylcholine).
22. The encapsulated composition of claim 14, wherein said resveratrol is derived from a natural source.
23. The encapsulated composition of claim 14, wherein said biological activity includes activating Sirtuin 1 enzymes.
24. A dietary supplement produced by the process of (a) deriving biologically active resveratrol material; (b) receiving a capsule including a head portion and a body portion into a filling chamber comprising a substantially oxygen-free environment; (c) at least partially filling the body portion with the biologically active resveratrol material; (d) positioning the head portion over the body portion such that the portions at least partially overlap; and (e) forming a fluid tight seal along the overlapping portions.
25. A dietary supplement including an encapsulated composition comprising resveratrol in its biologically active form, wherein said resveratrol maintains biological activity for at least four months after encapsulation.
26. The dietary supplement of claim 25, wherein said "biological activity includes stimulating Sirtuin 1 enzyme activity.
27. An encapsulated composition including biologically active small molecules and at least one of a chelating agent, an antioxidant, and an emulsifier, wherein said small molecules are capable of passing through a cell wall, entering the cell nucleus and altering gene- controlled enzymes located within the nucleus.
28. The encapsulated composition of claim 27, wherein said gene-controlled enzymes are Sirtuin 1 enzymes.
PCT/US2005/010466 2004-04-07 2005-03-28 Dietary supplement and method of processing same WO2005099761A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN2005800107544A CN1956733B (en) 2004-04-07 2005-03-28 Dietary supplement and method of processing same
JP2007507358A JP4963670B2 (en) 2004-04-07 2005-03-28 Nutritional supplements and methods for processing them
EP05731006A EP1735004A4 (en) 2004-04-07 2005-03-28 Dietary supplement and method of processing same
KR1020067020587A KR101213141B1 (en) 2004-04-07 2006-10-02 Dietary Supplement and Method of Processing Same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55995504P 2004-04-07 2004-04-07
US60/559,955 2004-04-07

Publications (1)

Publication Number Publication Date
WO2005099761A1 true WO2005099761A1 (en) 2005-10-27

Family

ID=35149781

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/010466 WO2005099761A1 (en) 2004-04-07 2005-03-28 Dietary supplement and method of processing same

Country Status (5)

Country Link
EP (1) EP1735004A4 (en)
JP (1) JP4963670B2 (en)
KR (1) KR101213141B1 (en)
CN (1) CN1956733B (en)
WO (1) WO2005099761A1 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007008548A2 (en) * 2005-07-07 2007-01-18 Sirtris Pharmaceuticals, Inc. Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
DE102007011676A1 (en) * 2007-03-09 2008-09-18 Hermann-Josef Wilhelm Preparation of active substances e.g. polyphenol resveratrol, useful e.g. as additives for plant protective agents, comprises extracting the active substances from leafage and rhizome of Fallopia plant named igniscum
WO2009082459A2 (en) * 2007-12-24 2009-07-02 Natrol, Inc. Anti-aging composition containing resveratrol and method of administration
DE102008035285A1 (en) * 2008-07-02 2010-01-07 Hermann-Josef Wilhelm Extraction of active substances from group of anthraquinone and phenols and/or polyphenols from a plant, where new plant variety Igniscum (CPVO 2007/0149) or Candy (CPVO 2007/1958) registered to variety protection is requisitioned as plant
DE102008037337A1 (en) * 2008-08-11 2010-02-25 Hermann-Josef Wilhelm Process for the preparation of active substances, in particular phenols from a plant
JP2010540444A (en) * 2007-09-20 2010-12-24 レスベラトロル パートナーズ, エルエルシー Composition comprising resveratrol for regulating the enrichment or activity of a gene product
US8911804B2 (en) 2008-07-31 2014-12-16 Shaklee Corporation Muscadine compositions with improved anti-oxidant activity
US8916528B2 (en) 2011-11-16 2014-12-23 Resveratrol Partners, Llc Compositions containing resveratrol and nucleotides
US9132162B2 (en) 2008-07-31 2015-09-15 Shaklee Corporation Muscadine compositions with anti-oxidant activity
US9173916B2 (en) 2008-07-31 2015-11-03 Shaklee Corporation Method of preparing a muscadine pomace extract
US9421189B2 (en) 2008-07-31 2016-08-23 Shaklee Corporation Method of preparing a muscadine pomace extract
US10967034B2 (en) 2016-07-19 2021-04-06 Shaklee Corporation Muscadine topical composition with low content of condensed tannin

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007096078A1 (en) * 2006-02-24 2007-08-30 Dsm Ip Assets B.V. Use of resveratrol and derivatives thereof for promoting the wellness state in mammals
TWI484918B (en) * 2008-07-31 2015-05-21 Shaklee Corp Method of preparing a muscadine pomace extract
JP5916321B2 (en) * 2011-09-05 2016-05-11 株式会社山田養蜂場本社 Transresveratrol-containing composition
US10335433B2 (en) * 2013-04-10 2019-07-02 Mimedx Group, Inc. NDGA polymers and metal complexes thereof
JP6343126B2 (en) * 2013-05-14 2018-06-13 森永製菓株式会社 Method for stabilizing stilbenes contained in plant extract or solution thereof, and plant extract containing stilbenes or solution thereof
JP6209360B2 (en) * 2013-05-14 2017-10-04 森永製菓株式会社 Piceatannol solution and method for stabilizing piceatannol solution
US9446142B2 (en) * 2013-05-28 2016-09-20 Mimedx Group, Inc. Polymer chelator conjugates
KR101990060B1 (en) 2017-07-21 2019-09-30 주식회사 송이산업 Method for preparation of resveratrol nano-capsue and the nano-capsule therefrom

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6190716B1 (en) * 1999-02-17 2001-02-20 Scott O. Galbreath, Jr. Method for preparing a grape derived product
US6469055B2 (en) * 1996-09-05 2002-10-22 Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2560051B2 (en) * 1987-12-11 1996-12-04 扶桑薬品工業株式会社 Light-shielding capsule formulation
US4963385A (en) * 1989-06-02 1990-10-16 Nabisco Brands, Inc. Stabilized emulsions containing highly unsaturated oils
BR9713212A (en) * 1996-09-20 2000-04-04 Howard Foundation Food supplements containing flavonol
DE19714450A1 (en) * 1997-04-08 1998-10-15 Schwabe Willmar Gmbh & Co Stable extract of Hypericum perforatum L., process for its preparation and pharmaceutical preparation
JP3617055B2 (en) * 1997-07-11 2005-02-02 東レ株式会社 Stable pharmaceutical composition containing 4,5-epoxymorphinan derivative
US6251478B1 (en) * 1999-12-22 2001-06-26 Balchem Corporation Sensitive substance encapsulation
US20030044474A1 (en) * 2001-08-03 2003-03-06 Shaklee Corporation High molecular weight, lipophilic, orally ingestible bioactive agents in formulations having improved bioavailability
JP2003119127A (en) * 2001-10-10 2003-04-23 Kanegafuchi Chem Ind Co Ltd Stable preparation of reduced coenzyme q
US20030133945A1 (en) * 2002-01-11 2003-07-17 Farley Michael Donald Natural food supplement
EP1499303A4 (en) * 2002-04-10 2007-07-25 Fred H Miller Multi-phase, multi-compartment capsular system
CA2499423A1 (en) * 2002-09-04 2004-03-18 Niraj Vasisht Microencapsulation of oxygen or water sensitive materials
CN1794925A (en) * 2003-05-27 2006-06-28 帝斯曼知识产权资产管理有限公司 Novel nutraceutical compositions and use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6469055B2 (en) * 1996-09-05 2002-10-22 Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
US6190716B1 (en) * 1999-02-17 2001-02-20 Scott O. Galbreath, Jr. Method for preparing a grape derived product

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1735004A4 *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007008548A3 (en) * 2005-07-07 2007-08-09 Sirtris Pharmaceuticals Inc Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
WO2007008548A2 (en) * 2005-07-07 2007-01-18 Sirtris Pharmaceuticals, Inc. Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
AU2006269459B2 (en) * 2005-07-07 2013-02-07 Sirtris Pharmaceuticals, Inc. Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
DE102007011676A1 (en) * 2007-03-09 2008-09-18 Hermann-Josef Wilhelm Preparation of active substances e.g. polyphenol resveratrol, useful e.g. as additives for plant protective agents, comprises extracting the active substances from leafage and rhizome of Fallopia plant named igniscum
JP2010540444A (en) * 2007-09-20 2010-12-24 レスベラトロル パートナーズ, エルエルシー Composition comprising resveratrol for regulating the enrichment or activity of a gene product
JP2014058574A (en) * 2007-09-20 2014-04-03 Resveratrol Partners Llc Compositions containing resveratrol for modulating concentration or activity of gene product
WO2009082459A3 (en) * 2007-12-24 2009-09-17 Natrol, Inc. Anti-aging composition containing resveratrol and method of administration
WO2009082459A2 (en) * 2007-12-24 2009-07-02 Natrol, Inc. Anti-aging composition containing resveratrol and method of administration
DE102008035285A1 (en) * 2008-07-02 2010-01-07 Hermann-Josef Wilhelm Extraction of active substances from group of anthraquinone and phenols and/or polyphenols from a plant, where new plant variety Igniscum (CPVO 2007/0149) or Candy (CPVO 2007/1958) registered to variety protection is requisitioned as plant
US8911804B2 (en) 2008-07-31 2014-12-16 Shaklee Corporation Muscadine compositions with improved anti-oxidant activity
US9132162B2 (en) 2008-07-31 2015-09-15 Shaklee Corporation Muscadine compositions with anti-oxidant activity
US9173916B2 (en) 2008-07-31 2015-11-03 Shaklee Corporation Method of preparing a muscadine pomace extract
US9421189B2 (en) 2008-07-31 2016-08-23 Shaklee Corporation Method of preparing a muscadine pomace extract
DE102008037337A1 (en) * 2008-08-11 2010-02-25 Hermann-Josef Wilhelm Process for the preparation of active substances, in particular phenols from a plant
US8916528B2 (en) 2011-11-16 2014-12-23 Resveratrol Partners, Llc Compositions containing resveratrol and nucleotides
US9226937B2 (en) 2011-11-16 2016-01-05 Resveratrol Partners, Llc Compositions containing resveratrol and nucleotides
US10967034B2 (en) 2016-07-19 2021-04-06 Shaklee Corporation Muscadine topical composition with low content of condensed tannin

Also Published As

Publication number Publication date
CN1956733B (en) 2012-10-10
EP1735004A4 (en) 2011-11-09
KR101213141B1 (en) 2012-12-17
CN1956733A (en) 2007-05-02
EP1735004A1 (en) 2006-12-27
JP4963670B2 (en) 2012-06-27
KR20070041427A (en) 2007-04-18
JP2007532543A (en) 2007-11-15

Similar Documents

Publication Publication Date Title
US20050158376A1 (en) Dietary supplement and method of processing same
EP1735004A1 (en) Dietary supplement and method of processing same
Dhalaria et al. Bioactive compounds of edible fruits with their anti-aging properties: A comprehensive review to prolong human life
Smeriglio et al. Chemistry, pharmacology and health benefits of anthocyanins
KR101464500B1 (en) All natural multivitamin and multimineral dietary supplement formulations for enhanced absorption and biological utilization
Que et al. In vitro and vivo antioxidant activities of daylily flowers and the involvement of phenolic compounds
Shabir et al. Promising bioactive properties of quercetin for potential food applications and health benefits: A review
Bhardwaj et al. Nutritional and therapeutic potential of bael (Aegle marmelos Corr.) fruit juice: a review
Akinpelu et al. The in vitro antioxidant property of methanolic extract of Afzelia africana (Smith.)
Saada et al. Grape seed extract Vitis vinifera protects against radiation‐induced oxidative damage and metabolic disorders in rats
Kortei et al. Evaluating the effect of gamma radiation on the total phenolic content, flavonoids, and antioxidant activity of dried Pleurotus ostreatus ((Jacq. ex. Fr) Kummer) stored in packaging materials
Halliwell et al. Diet-derived antioxidants: the special case of ergothioneine
Holland et al. Pomegranate: aspects concerning dynamics of health beneficial phytochemicals and therapeutic properties with respect to the tree cultivar and the environment
Bouftira et al. Characterization of cosmetic cream with Mesembryanthemum crystallinum plant extract: influence of formulation composition on physical stability and anti‐oxidant activity
Amani et al. Loading ferulic acid into β-cyclodextrin nanosponges; antibacterial activity, controlled release and application in pomegranate juice as a copigment agent
Adetuyi et al. Banana peel as a source of nutraceuticals
Sun et al. Protective effects of blueberry anthocyanin extracts on hippocampal neuron damage induced by extremely low-frequency electromagnetic field
Guo et al. Antioxidant and antidiabetic activities of Ulmus davidiana extracts
Abdelaleem et al. Modulatory role of selenium nanoparticles and grape seed extract mixture on oxidative stress biomarkers in diabetic irradiated rats
Wafa et al. Antioxidant, anti-inflammatory and antimicrobial activities of aqueous and methanolic extract of Rosmarinus eriocalyx Jord. & Fourr.
Rahim et al. Antioxidant Activity and its Interaction Effect on Polyherbal Formulations of Nephrodium inophyllum, Polygonum minus Annona squamosal L. and Stevia rebaudiana
Elufioye et al. Anti-oxidant capacity and phenolic content of methanolic extract of Cleome viscosa L. whole plant and its derived fractions.
Butt et al. Health benefits of anthocyanins in black carrot (Daucus carota)
Engwa et al. In vitro and in vivo antioxidant activity of aqueous and ethanol leaf extracts of Murraya koenigii
Mandal et al. Targeting Oxidative Stress in Cancer: Opportunity for Natural and Synthetic Compounds, and Cancer Stem Cell Therapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005731006

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007507358

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 200580010754.4

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 1020067020587

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWP Wipo information: published in national office

Ref document number: 2005731006

Country of ref document: EP